Samsung Biologics Inks Manufacturing Deal with AstraZeneca
SEOUL, Sept. 22 (Korea Bizwire) — South Korea’s top pharmaceutical firm, Samsung Biologics Co., said Tuesday it has signed a long-term supply agreement, valued at approximately US$330.8 million, with British-Swedish bio giant AstraZeneca Plc. Under the contract manufacturing organization (CMO) agreement, Samsung Biologics will provide large-scale commercial manufacturing for drug substance in its third plant [...]